Mission Bio Inc. and Fulgent Genetics, Inc. (NASDAQ: FLGT) have entered into a groundbreaking partnership to bring the power of single-cell multi-omics to the Fulgent Genetics menu of services.
The Tapestri Platform, developed by Mission Bio, will enable Fulgent Genetics to offer a fully customizable suite of services that include whole genome, whole exome, RNA sequencing, tumor profiling, methylation sequencing, liquid biopsy, single-cell sequencing, spatial biology, and pathology services.
Furthermore, Fulgent Genetics will evaluate the Tapestri Platform for applications in clinical development to advance the drug development and approval process.
In recent years, clinical trials have seen a marked shift towards precision oncology, and the Tapestri Platform’s single-cell analysis capabilities are paving the way forward. By providing an unprecedented level of sensitivity and resolution, single-cell analysis enables the discovery of biomarkers to more effectively stratify trial cohorts.
Moreover, this technology can uncover mechanisms of treatment resistance and monitor residual levels of disease during treatment, allowing for more precise patient stratification and improved clinical trial outcomes. In short, single-cell analysis has the potential to revolutionize the field of precision oncology.
The increasing adoption of the Tapestri Platform for translational research and clinical development by cancer centers and pharma companies around the world is a testament to the power of single-cell multi-omics.
To make it easier and faster for biopharmaceutical customers to generate data for more precise clinical trials, Fulgent Genetics is teaming up with Mission Bio, and Dr. Hanlin (Harry) Gao M.D., Ph.D., D.A.B.M.G., F.A.C.M.G., Chief Scientific Officer of Fulgent Genetics, is excited to see the impact this partnership will have.
For pharmaceutical customers looking for a comprehensive genomic portfolio, Fulgent Genetics offers the ideal one-stop shop. With its full scope and end-to-end services, Fulgent Genetics is poised to become a go-to partner for pharma customers.
Moreover, Mission Bio’s internal Pharma Assay Development (PAD) services are available for those who wish to take advantage of the single-cell multi-omics expertise offered by Fulgent Genetics. Furthermore, the soon-to-be-completed CAP CLIA lab validation of the Tapestri Platform is set to further strengthen Fulgent Genetics’ position as a leader in the field.
Customers now have the opportunity to explore the power of the Tapestri Platform, with its comprehensive suite of single-cell multi-omics and scMRD assays, through Fulgent Genetics’ renowned laboratories. Unlock the potential of your data and enjoy unparalleled insights into the world of single-cell science.
About Mission Bio
Mission Bio is revolutionizing the life sciences industry by providing researchers with the tools they need to uncover new therapies for a range of diseases. By utilizing a multi-omics approach, Mission Bio is streamlining the process of bringing innovative cell and gene therapies to market.
Founded in 2014, the company has secured investments from several leading venture capital firms, such as Novo Growth, Cota Capital, Agilent Technologies, and Mayfield Fund. Through their cutting-edge work, Mission Bio is opening up new pathways to health and driving the future of medicine.
The Tapestri Platform is revolutionizing the way researchers understand complex biological systems. By providing the ability to analyze both DNA and protein from the same sample at single-cell resolution, it is enabling a comprehensive understanding of cellular activity unlike ever before.
Already, the platform is being used by customers at leading research centers, pharmaceutical, and diagnostics companies worldwide to develop treatments and eventually cures for cancer. Tapestri is the only commercialized multi-omics platform with this capability, giving researchers around the globe the power to interrogate every molecule in a cell and move us closer to a world free of disease.
Fulgent is a pioneering technology-driven company, focused on transforming healthcare through precision medicine. With an established clinical diagnostic business and an innovative therapeutic development business, Fulgent provides molecular diagnostic testing services, comprehensive genetic testing, and high-quality anatomic pathology laboratory services to physicians and patients alike.
At the same time, the company is developing drug candidates to treat a broad range of cancers with a novel nanoencapsulation and targeted therapy platform, designed to enhance the therapeutic window and pharmacokinetic profile of existing and new cancer drugs. In sum, Fulgent is determined to become a leader in the field of precision medicine.